Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Assessment of immunogenicity and drug activity in patient sera by flow-induced dispersion analysis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. A new method to quantify left ventricular mass by 2D echocardiography

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Multi-modal and multi-scale clinical retinal imaging system with pupil and retinal tracking

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Low adherence to the guideline for the acute treatment of migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Biochemical abnormalities among patients referred for celiac disease antibody blood testing in a primary health care setting

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. CXCL13 predicts long term radiographic status in early rheumatoid arthritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Rheumatology: Biosimilars are here to stay

    Research output: Contribution to journalEditorialResearchpeer-review

  3. Waiting for JAK inhibitor safety data

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Biopharmaceuticals have revolutionized the treatment of many diseases such as diabetes, cancer, and autoimmune disorders. These complex entities provide unique advantages like high specificity towards their target. Unfortunately, biopharmaceuticals are also prone to elicit undesired immunogenic responses (immunogenicity), compromising treatment efficacy as well as patient safety due to severe adverse effects including life threatening conditions. Current immunogenicity assays are hampered by immobilization procedures, complicated sample pre-treatment, or rely on cell-based methods which all prevent reliable and continuous monitoring of patients. In this work, we present Flow Induced Dispersion Analysis (FIDA) for assessment of immunogenicity and drug activity in serum samples from arthritis patients receiving adalimumab. FIDA is a first principle technique for size-based characterization of biomolecules and their complexes under biologically relevant conditions. The FIDA methodology rely on an absolute and quantitative readout (hydrodynamic radius) thus reducing the need for positive and negative controls. Here, FIDA is applied for evaluating active adalimumab in serum by studying the interaction with its target tumor necrosis factor alpha (TNF-α). We report proof of principle for a quantitative approach for stratifying patients exhibiting presence of neutralizing and non-neutralizing antibodies based on their individual drug activity pattern. Further, it can be applied to any biopharmaceutical having soluble drug targets and it holds potential in a companion diagnostics setting.

Original languageEnglish
Article number4670
JournalScientific Reports
Volume12
Issue number1
Pages (from-to)4670
ISSN2045-2322
DOIs
Publication statusPublished - 2022

Bibliographical note

© 2022. The Author(s).

ID: 75715379